News|Articles|October 31, 2024
WCG Meets Enrollment 24 Months Early for Top 5 Pharma’s Decentralized Trial
Author(s)WCG Clinical
A sponsor needed to get their Phase II dermatology study enrollment back on track. The study was underway for 11 months across 32 sites globally with only 20 subjects enrolled to date. With WCG support, enrollment was concluded 24 months ahead of schedule.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
2
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
3
Reducing Site Burden Through Better Technology Integration in Clinical Trials
4
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
